129 related articles for article (PubMed ID: 27402614)
21. The HIV protease inhibitor nelfinavir down-regulates RET signaling and induces apoptosis in medullary thyroid cancer cells.
Kushchayeva Y; Jensen K; Recupero A; Costello J; Patel A; Klubo-Gwiezdzinska J; Boyle L; Burman K; Vasko V
J Clin Endocrinol Metab; 2014 May; 99(5):E734-45. PubMed ID: 24483157
[TBL] [Abstract][Full Text] [Related]
22. A synonymous RET substitution enhances the oncogenic effect of an in-cis missense mutation by increasing constitutive splicing efficiency.
Pecce V; Sponziello M; Damante G; Rosignolo F; Durante C; Lamartina L; Grani G; Russo D; di Gioia CR; Filetti S; Verrienti A
PLoS Genet; 2018 Oct; 14(10):e1007678. PubMed ID: 30321177
[TBL] [Abstract][Full Text] [Related]
23. Apoptotic cell death induction and angiogenesis inhibition in large established medullary thyroid carcinoma xenografts by Ret inhibitor RPI-1.
Petrangolini G; Cuccuru G; Lanzi C; Tortoreto M; Belluco S; Pratesi G; Cassinelli G; Zunino F
Biochem Pharmacol; 2006 Aug; 72(4):405-14. PubMed ID: 16756963
[TBL] [Abstract][Full Text] [Related]
24. Somatic VHL gene alterations in MEN2-associated medullary thyroid carcinoma.
Koch CA; Brouwers FM; Vortmeyer AO; Tannapfel A; Libutti SK; Zhuang Z; Pacak K; Neumann HP; Paschke R
BMC Cancer; 2006 May; 6():131. PubMed ID: 16707008
[TBL] [Abstract][Full Text] [Related]
25. Metabolomics signatures of a subset of RET variants according to their oncogenic risk level.
Veyrat-Durebex C; Bouzamondo N; Le Mao M; Chao de la Barca JM; Bris C; Dieu X; Simard G; Gadras C; Tessier L; Drui D; Borson-Chazot F; Barlier A; Reynier P; Prunier-Mirebeau D
Endocr Relat Cancer; 2019 Mar; 26(3):379-389. PubMed ID: 30653460
[TBL] [Abstract][Full Text] [Related]
26. Proteomics study of medullary thyroid carcinomas expressing RET germ-line mutations: identification of new signaling elements.
Gorla L; Mondellini P; Cuccuru G; Miccichè F; Cassinelli G; Cremona M; Pierotti MA; Lanzi C; Bongarzone I
Mol Carcinog; 2009 Mar; 48(3):220-231. PubMed ID: 18756447
[TBL] [Abstract][Full Text] [Related]
27. Clinical significance of RET and RAS mutations in sporadic medullary thyroid carcinoma: a meta-analysis.
Vuong HG; Odate T; Ngo HTT; Pham TQ; Tran TTK; Mochizuki K; Nakazawa T; Katoh R; Kondo T
Endocr Relat Cancer; 2018 Jun; 25(6):633-641. PubMed ID: 29615431
[TBL] [Abstract][Full Text] [Related]
28. Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinomas.
Dvorakova S; Vaclavikova E; Sykorova V; Vcelak J; Novak Z; Duskova J; Ryska A; Laco J; Cap J; Kodetova D; Kodet R; Krskova L; Vlcek P; Astl J; Vesely D; Bendlova B
Mol Cell Endocrinol; 2008 Mar; 284(1-2):21-7. PubMed ID: 18282654
[TBL] [Abstract][Full Text] [Related]
29. Aggressive inherited and sporadic medullary thyroid carcinomas display similar oncogenic pathways.
Ameur N; Lacroix L; Roucan S; Roux V; Broutin S; Talbot M; Dupuy C; Caillou B; Schlumberger M; Bidart JM
Endocr Relat Cancer; 2009 Dec; 16(4):1261-72. PubMed ID: 19675075
[TBL] [Abstract][Full Text] [Related]
30. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M
J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268
[TBL] [Abstract][Full Text] [Related]
31. The mismatch repair system is not affected in medullary thyroid carcinoma independent of stromal desmoplasia or ret proto-oncogene mutation.
Ingenwerth M; Goetz M; Schmid KW; Theurer S
Ann Diagn Pathol; 2020 Feb; 44():151445. PubMed ID: 31862521
[TBL] [Abstract][Full Text] [Related]
32. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.
Elisei R; Cosci B; Romei C; Bottici V; Renzini G; Molinaro E; Agate L; Vivaldi A; Faviana P; Basolo F; Miccoli P; Berti P; Pacini F; Pinchera A
J Clin Endocrinol Metab; 2008 Mar; 93(3):682-7. PubMed ID: 18073307
[TBL] [Abstract][Full Text] [Related]
33. [MEN 2A with double mutation in RET gene: Ectopic ACTH production in medullary thyroid carcinoma].
Ares J; Díaz-Naya L; Martín-Nieto A; Pertierra J
Med Clin (Barc); 2016 May; 146(9):419-20. PubMed ID: 26724871
[No Abstract] [Full Text] [Related]
34. The prevalence of somatic RAS mutations in medullary thyroid cancer - a Polish population study.
Oczko-Wojciechowska M; Pfeifer A; Rusinek D; Pawlaczek A; Zebracka-Gala J; Kowalska M; Kowal M; Swierniak M; Krajewska J; Gawlik T; Chmielik E; Czarniecka A; Szpak-Ulczok S; Jarząb B
Endokrynol Pol; 2015; 66(2):121-5. PubMed ID: 25931041
[TBL] [Abstract][Full Text] [Related]
35. Mammalian target of rapamycin pathway activation is associated to RET mutation status in medullary thyroid carcinoma.
Rapa I; Saggiorato E; Giachino D; Palestini N; Orlandi F; Papotti M; Volante M
J Clin Endocrinol Metab; 2011 Jul; 96(7):2146-53. PubMed ID: 21543427
[TBL] [Abstract][Full Text] [Related]
36. Use of Tyrosine Kinase Inhibitors for Treatment of Medullary Thyroid Carcinoma.
Dadu R; Hu MN; Grubbs EG; Gagel RF
Recent Results Cancer Res; 2015; 204():227-49. PubMed ID: 26494392
[TBL] [Abstract][Full Text] [Related]
37. Combined RET and Ki-67 assessment in sporadic medullary thyroid carcinoma: a useful tool for patient risk stratification.
Mian C; Pennelli G; Barollo S; Cavedon E; Nacamulli D; Vianello F; Negro I; Pozza G; Boschin IM; Pelizzo MR; Rugge M; Mantero F; Girelli ME; Opocher G
Eur J Endocrinol; 2011 Jun; 164(6):971-6. PubMed ID: 21422198
[TBL] [Abstract][Full Text] [Related]
38. The importance of the RET gene in thyroid cancer and therapeutic implications.
Salvatore D; Santoro M; Schlumberger M
Nat Rev Endocrinol; 2021 May; 17(5):296-306. PubMed ID: 33603219
[TBL] [Abstract][Full Text] [Related]
39. Germline ESR2 mutation predisposes to medullary thyroid carcinoma and causes up-regulation of RET expression.
Smith J; Read ML; Hoffman J; Brown R; Bradshaw B; Campbell C; Cole T; Navas JD; Eatock F; Gundara JS; Lian E; Mcmullan D; Morgan NV; Mulligan L; Morrison PJ; Robledo M; Simpson MA; Smith VE; Stewart S; Trembath RC; Sidhu S; Togneri FS; Wake NC; Wallis Y; Watkinson JC; Maher ER; McCabe CJ; Woodward ER
Hum Mol Genet; 2016 May; 25(9):1836-45. PubMed ID: 26945007
[TBL] [Abstract][Full Text] [Related]
40. RET exon 11 (G691S) polymorphism is significantly more frequent in sporadic medullary thyroid carcinoma than in the general population.
Elisei R; Cosci B; Romei C; Bottici V; Sculli M; Lari R; Barale R; Pacini F; Pinchera A
J Clin Endocrinol Metab; 2004 Jul; 89(7):3579-84. PubMed ID: 15240649
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
